Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Alcohol Use Disorder

Alcohol Use Disorder Clinical Trial

Official title:

Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) for Reduction of Negative Affect and Treatment of Alcohol Use Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03829761
• Other study ID #: 14918
• Secondary ID: R21AA026573
• Status: Completed
• Phase: N/A
• Start date: February 20, 2019
• Est. completion date: September 7, 2023

Study information

• Verified date: October 2023
• Source: The Mind Research Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the current study is to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) on self-reported negative affect, cerebellar brain activation and alcohol use outcomes in alcohol use disorder (AUD).

Description:

To achieve study aims, 34 treatment seeking adults with AUD will be recruited from local intensive outpatient (IOP) treatment programs and randomized to treatment with either inhibitory 1Hz rTMS to cerebellar vermis given daily for 2 weeks (total of 10 sessions) or sham. Alcohol use outcomes, self-reported negative affect, and craving will be obtained at baseline, 1 day, 1 week and 6 weeks following rTMS termination. An fMRI scan during a Stroop task will be obtained at baseline and 1 day after the final rTMS session.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 7, 2023
• Est. primary completion date: September 7, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females age 18-65 meeting DSM-V criteria for moderate or severe AUD in the past year;
• Interested in cutting down or quitting drinking;
• Able to provide voluntary informed consent;
• Have at least 4 heavy drinking days (= 5 drinks per day for men, and =4 for women) in the past 60 days;
• Currently receiving treatment for alcohol use disorder.

Exclusion Criteria:

• Severe neurological conditions (TBI/stroke/history of a seizure/dementia and other significant cognitive illnesses);
• Other urgent medical problems, as determined by the study physician from the history and physical exam;
• Schizophrenia, schizoaffective disorder, bipolar I disorder
• Suicidal thoughts (intent or plan) in the last month;
• Current moderate or severe other SUD (except nicotine or marijuana) or other drug (except nicotine or marijuana) use in the past month;
• Active legal problems with the potential to result in incarceration;
• Pregnancy or lactation, or child bearing age and sexually active but not on birth control (barrier methods allowed);
• Current daily use of anti-craving medications, antidepressants (at doses considered therapeutic for depression), benzodiazepines, antipsychotics (at doses considered therapeutic for psychosis or mood stabilization), mood stabilizers (at doses considered therapeutic for mood stabilization);
• Have previously undergone rTMS (to assure the blind is effective);
• Personal or familial (in first degree relatives) history of epilepsy;
• Any contraindication for Magnetic Resonance Imaging (MRI) or TMS including metal shards or certain implants (pacemakers etc.) in the body.

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism

Intervention

Device:
• Repetitive transcranial magnetic stimulation (rTMS)
Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
• Sham transcranial magnetic stimulation
Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.

Locations

Country	Name	City	State
United States	The Mind Research Network	Albuquerque	New Mexico

Sponsors (2)

Lead Sponsor	Collaborator
The Mind Research Network	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to drinking relapse as measured by the Time Line Follow Back	Time to drinking relapse as measured by the Time Line Follow Back from baseline in days.	8 weeks
Primary	Change in percent days abstinent as measured by the Time Line Follow Back	Change in percent days abstinent as measured by the Time Line Follow Back from the 90 days prior to day 1 to day 14-21 (post-treatment).	3 weeks
Primary	Change in self reported negative affect as measured by the Promise anger, anxiety and depression scales	Change in self reported negative affect as measured by the Promise anger, anxiety and depression scale T scores from baseline to day 15 (post-treatment).	2 weeks
Primary	Change in cerebellar brain activation as indicated by percent signal change in the medial cerebellum during incongruent minus congruent trials during a multisensory Stroop task during fMRI	Change in cerebellar brain activation as indicated by percent signal change in the medial cerebellum during incongruent minus congruent trials during a multisensory Stroop task during fMRI from baseline to day 15 (post-treatment). This will be calculated using a mask derived from preliminary data from a sample of 33 individuals with AUD at a single timepoint. Activation in this brain region was correlated with depression, anxiety, and recent drinking. Manuscript describing this result is under review (Wilcox et al.), and another manuscript describes the task in question (Wilcox et al. 2014 Cognitive Control Network Function in Alcohol Use Disorder Before and During Treatment With Lorazepam. Subst Use Misuse.	2 weeks